JAC Advance Access published online on February 18, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh129
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief report
1 Genesoft Pharmaceuticals,
Inc., 7300 Shoreline Court, South San Francisco, CA, USA;
* Corresponding author. E-mail: dlofland{at}genesoft.com.
Received 2 September 2003
; revised 20 November 2003
; accepted 23 December 2003
Objectives: BB-83698 is a peptide
deformylase inhibitor currently in clinical trials in Europe. The
purpose of this study was to provide additional susceptibility data
from clinical isolates, including drug-resistant strains. Methods: The in vitro activities
of BB-83698 and comparators were determined against 281 streptococci,
154 Staphylococcus aureus, 110 Haemophilus
influenzae and 50 Moraxella catarrhalis strains
selected for their resistance phenotypes. Broth microdilution MICs
and MBCs were determined according to NCCLS guidelines. Results: The MIC90s were 0.25-0.5
mg/L for S. pneumoniae, including penicillin-,
erythromycin-, levofloxacin- and multidrug-resistant strains. The
MIC90s for Streptococcus pyogenes and Streptococcus agalactiae were 0.12 mg/L and for
viridans streptococci, the MIC90 was 0.5 mg/L. Against S. aureus, including oxacillin- and levofloxacin-resistant
strains, and vancomycin-intermediate strains, the MIC90 was
8 mg/L. Against Conclusions: Although BB-83698 has reduced in vitro activity against H. influenzae,
it is a potent antimicrobial with excellent activity against streptococci
and Moraxella.
Keywords: antimicrobials, antibiotics, bactericidal, MIC,
MBC
In vitro antibacterial activity
of the peptide deformylase
inhibitor BB-83698
2 British Biotech Pharmaceuticals
Ltd., Oxford, UK;
3 Focus
Technologies, Herndon, VA, USA
-lactamase-negative
and -positive H. influenzae, the MIC90s
were 32 and 64 mg/L, respectively, and against both -lactamase-negative
and -positive M. catarrhalis the MIC90 was
0.12 mg/L. In MBC studies, the ratio of MBC/MIC was 1:1 or 2:1 against
31% of S. pneumoniae, 33% of S. aureus, 63% of H. influenzae and
9% of M. catarrhalis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Huang, G. S. Van Aller, A. N. Taylor, J. J. Kerrigan, W.-S. Liu, J. M. Trulli, Z. Lai, D. Holmes, K. M. Aubart, J. R. Brown, et al. Phylogenomic and Biochemical Characterization of Three Legionella pneumophila Polypeptide Deformylases. J. Bacteriol., July 1, 2006; 188(14): 5249 - 5257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bell, J. D. Turnidge, M. Inoue, S. Kohno, Y. Hirakata, Y. Ono, and R. N. Jones Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan J. Antimicrob. Chemother., February 1, 2005; 55(2): 276 - 278. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ramanathan-Girish, J. McColm, J. M. Clements, P. Taupin, S. Barrowcliffe, J. Hevizi, S. Safrin, C. Moore, G. Patou, H. Moser, et al. Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4835 - 4842. [Abstract] [Full Text] [PDF]
|
|